Drug Trial Radar · NCT03892577
Real-world Study for Patients With Advanced Hepatobiliary Tumors
Last checked: Nov 19, 2026Latest source record: Mar 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
3,000
Planned (sponsor's estimate)
Start
Jul 1, 2017
Primary completion
Oct 1, 2023
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Peking Union Medical College HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- OrigiMed
- First posted
- Mar 27, 2019
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigators design a large sample size study in the real-world to explore whether targeted therapy and immunotherapy can improve the survival, quality of life and drug safety of patients with advanced hepatobiliary tumors, and analyze the correlation between genetic variation and the effectiveness of therapy.
Conditions
- Objective Response Rate
- Progression-free Survival
- Overall Survival
- Disease Control Rate
- Duration of Response
- Five-year Survival Rate
- Quality of Life
Interventions
Precision oncology including targeted therapy and immunotherapyDrug
Therapeutic regimens are based on the clinicopathological features, genomic alterations, advices from multidisciplinary tumor board and willings from patients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: two years
- Progression-free Survival (PFS)Time frame: six months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chinese Academy of Medical Sciences & Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.